Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales

Ceftazidime-avibactam use for KPC-Kp infections: a retrospective observational multicenter study

(2021) Mario Tumbarello et al.   CLINICAL INFECTIOUS DISEASES

Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales: Risk Factors for Mortality, Antimicrobial Therapy and Treatment Outcomes from a Prospective Multicenter Study

(2021) Chaoe Zhou et al.   Infection and Drug Resistance

Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase–Producing Enterobacterales During a Regional Outbreak

(2020) Marco Falcone et al.   Open Forum Infectious Diseases

Clinical and Microbiologic Analysis of Risk Factors for Mortality in Patients with Carbapenem-Resistant Enterobacteriaceae Bacteremia

(2020) Hyeonji Seo et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort

(2020) Juan José Castón et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Ceftazidime/avibactam in the era of carbapenemase-producing Klebsiella pneumoniae: experience from a national registry study

(2020) I Karaiskos et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Management of carbapenem-resistant Enterobacteriaceae infections

(2019) E. Durante-Mangoni et al.   CLINICAL MICROBIOLOGY AND INFECTION

Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018

(2019) Kati Räisänen et al.   Eurosurveillance

Carbapenem-resistant Enterobacteriaceae: An emerging bacterial threat

(2019) Joseph D. Lutgring   SEMINARS IN DIAGNOSTIC PATHOLOGY

Use of meropenem in treating carbapenem-resistant Enterobacteriaceae infections

(2019) Renato Pascale et al.   Expert Review of Anti-Infective Therapy

A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections

(2019) Akosua A. Agyeman et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

A Retrospective Analysis of Risk Factors and Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Bacteremia in Nontransplant Patients

(2019) Tingting Xiao et al.   JOURNAL OF INFECTIOUS DISEASES

Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial

(2018) Antoni Torres et al.   LANCET INFECTIOUS DISEASES

Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant Enterobacteriaceae Bacteremia

(2018) Xiaojuan Wang et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The use of polymyxins to treat carbapenem resistant infections in neonates and children

(2018) Reenu Thomas et al.   EXPERT OPINION ON PHARMACOTHERAPY

Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae

(2017) Liangfei Xu et al.   Annals of Clinical Microbiology and Antimicrobials

Combination Regimens for Treatment of Carbapenem-Resistant Klebsiella pneumoniae Bloodstream Infections

(2016) A. Gomez-Simmonds et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

(2016) Ryan K. Shields et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program

(2016) John E. Mazuski et al.   CLINICAL INFECTIOUS DISEASES

Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms

(2016) Roopali Sharma et al.   CLINICAL THERAPEUTICS

Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing

(2016) Nikolas J. Onufrak et al.   CLINICAL THERAPEUTICS

Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?

(2016) Thien B. Tran et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections

(2016) Wentao Ni et al.   MEDICINE

Carbapenemase-Producing Klebsiella pneumoniae Bloodstream Infections: Lowering Mortality by Antibiotic Combination Schemes and the Role of Carbapenems

(2014) George L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Global Challenge of Carbapenem-Resistant Enterobacteriaceae in Transplant Recipients and Patients With Hematologic Malignancies

(2014) M. J. Satlin et al.   CLINICAL INFECTIOUS DISEASES

Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?

(2011) Steven Y. C. Tong et al.   Seminars in Immunopathology

Prospective Observational Study of the Impact of VIM-1 Metallo- -Lactamase on the Outcome of Patients with Klebsiella pneumoniae Bloodstream Infections

(2009) G. L. Daikos et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007

(2008) Alicia I. Hidron et al.   INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY